Edgewise Therapeutics Inc...

NASDAQ: EWTX · Real-Time Price · USD
14.15
0.22 (1.58%)
At close: Aug 15, 2025, 3:59 PM
14.31
1.10%
After-hours: Aug 15, 2025, 05:00 PM EDT

Edgewise Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
2.12M 2.12M 2.12M 2.25M 2.25M 2.25M 2.25M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
4.47M 4.44M 4.41M 3.88M 2.04M 1.94M 1.66M 1.22M 935K 652K 538K 524K 423K 320K 272K 194K 130K 79K
Gross Profit
-2.35M -2.32M -2.29M -1.63M 212K 309K 593K -1.22M -935K -652K -538K -524K -423K -320K -272K -194K -130K -79K
Operating Income
-174.54M -170.04M -158.83M -147.15M -136.17M -123.41M -114.36M -102.57M -91.38M -82.54M -71.66M -62.4M -57.22M -51.18M -43.22M -36.74M -27.3M -20.8M
Interest Income
23.84M 23.95M 25.02M 22.86M 20.3M 17.56M 14.19M 13.14M 10.16M 6.72M 4.02M 1.48M 843K 526K 402K 278K 152K 48K
Pretax Income
-150.7M -146.09M -133.81M -124.29M -115.88M -105.85M -100.16M -89.44M -81.22M -75.82M -67.64M -60.92M -56.37M -50.66M -42.81M -36.46M -27.15M -20.75M
Net Income
-150.7M -146.09M -133.81M -124.29M -115.88M -105.85M -97.06M -83.66M -74.69M -68.86M -63.62M -59.57M -55.78M -50.49M -42.81M -36.46M -27.15M -20.75M
Selling & General & Admin
35.74M 34.06M 31.87M 28.77M 26.22M 24.63M 23.45M 22.74M 21.44M 19.75M 17.63M 15.89M 14.72M 13.23M 11.03M 8.5M 5.71M 3.42M
Research & Development
139.86M 136.5M 126.97M 117.33M 108.89M 98.25M 90.91M 79.83M 69.94M 62.78M 54.03M 46.51M 42.49M 37.95M 32.19M 28.24M 21.6M 17.38M
Other Expenses
-1.06M -1.06M -1.06M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
174.54M 169.5M 157.77M 146.09M 135.12M 122.88M 114.36M 102.57M 91.38M 82.54M 71.66M 62.4M 57.22M 51.18M 43.22M 36.74M 27.3M 20.8M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
106K 52K n/a -106K -106K -52K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
174.54M 170.04M 158.83M 147.15M 136.17M 123.41M 114.36M 102.57M 91.38M 82.54M 71.66M 62.4M 57.22M 51.18M 43.22M 36.74M 27.3M 20.8M
Income Tax Expense
n/a n/a n/a n/a n/a n/a -3.11M -5.77M -6.54M -6.96M -4.02M -1.35M -590K -166K n/a n/a n/a n/a
Shares Outstanding (Basic)
104.94M 95.13M 92.41M 93.81M 93.52M 87.57M 64.77M 63.46M 63.38M 63.27M 63.23M 51.84M 49.62M 49.54M 49.26M 49.26M 49.26M 1.56M
Shares Outstanding (Diluted)
104.94M 95.13M 92.41M 93.81M 93.52M 87.57M 64.77M 63.46M 63.38M 63.27M 63.23M 51.84M 49.62M 49.54M 49.26M 49.26M 49.26M 1.56M
EPS (Basic)
-1.55 -1.55 -1.45 -1.5 -1.55 -1.55 -1.53 -1.32 -1.23 -1.21 -1.19 -1.19 -1.13 -1.02 -5.1 -5.15 -5.07 -5.05
EPS (Diluted)
-1.55 -1.55 -1.45 -1.5 -1.55 -1.55 -1.53 -1.32 -1.23 -1.21 -1.19 -1.19 -1.13 -1.02 -5.1 -5.15 -5.07 -5.05
EBITDA
-167.43M -162.45M -150.77M -145.12M -134.29M -121.58M -112.81M -101.42M -90.58M -82.06M -71.25M -62M -56.85M -50.86M -42.94M -36.49M -27.07M -20.58M
EBIT
-157.01M -159M -152.95M -147.15M -136.17M -123.41M -114.36M -102.57M -91.38M -82.54M -71.66M -62.4M -57.22M -51.18M -43.22M -36.74M -27.3M -20.8M
Depreciation & Amortization
1.78M 2.32M 2.29M 2.19M 2.04M 1.94M 1.66M 1.22M 935K 652K 538K 524K 423K 320K 272K 244K 230K 224K